+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
ID07540273

Evaluating Portable Versus Clinic-Based Transcutaneous Tibial Nerve Stimulation for Overactive Bladder in Adults

Led by SEZGIN · Updated on 2026-09-18

60

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying adults aged 18 to 65 with overactive bladder OAB to see if using a portable nerve stimulation device during daily life can reduce symptoms. The trial compares this ambulatory approach to traditional clinic-based treatment, aiming to answer whether home use of transcutaneous tibial nerve stimulation TTNS reduces urgency episodes and improves bladder symptoms and quality of life similarly to clinic treatment. Participants are randomly assigned to one of two groups. Group 1 receives clinic-based TTNS sessions twice a week for 2 weeks, each lasting 30 minutes using surface electrodes near the ankle. Group 2 uses a portable TENS device at home during daily activities when feeling urgency, over a 2-week period. Both groups use identical stimulation settings of 20 Hz frequency and 200 microseconds pulse width. Group 2 participants receive training on how to apply the device. During the study, participants complete bladder symptom questionnaires and a 3-day voiding diary before and after treatment. Quality of life is assessed at the start and after 4 weeks. Researchers monitor adherence, patient satisfaction, and any side effects. The main outcomes measured include changes in OAB symptom scores and quality of life questionnaires, with follow-up at 4 weeks after treatment begins.

CONDITIONS

Brief Title

Effectiveness of Ambulatory Transcutaneous Tibial Nerve Stimulation for Overactive Bladder

Research Team

V

Veysel Sezgin Sezgin, M.D

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here